Evidence map›Paper›PMID 26999210›Full record

ReviewToxins2016

Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction.

Joseph J Janicki, Michael B Chancellor, Jonathan Kaufman, Michele A Gruber, David D Chancellor

Open access · goldAbstract readReview
In one paragraph

Review in Toxins, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Joseph J JanickiLipella Pharmaceuticals, Pittsburgh, PA 19019, USA. joe.janicki@lipella.com.
Michael B ChancellorLipella Pharmaceuticals, Pittsburgh, PA 19019, USA. chancellormb@gmail.com.
Jonathan KaufmanLipella Pharmaceuticals, Pittsburgh, PA 19019, USA. mdato@aol.com.
Michele A GruberLipella Pharmaceuticals, Pittsburgh, PA 19019, USA. michele.anthony@lipella.com.
David D ChancellorLipella Pharmaceuticals, Pittsburgh, PA 19019, USA. daviddchancellor@gmail.com.
Lipella Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder drug delivery via catheter instillation is a widely used treatment for recurrence of superficial bladder cancer. Intravesical instillation of liposomal botulinum toxin has recently shown promise in the treatment of overactive bladder and interstitial cystitis/bladder pain syndrome, and studies of liposomal tacrolimus instillations show promise in the treatment of hemorrhagic cystitis. Liposomes are lipid vesicles composed of phospholipid bilayers surrounding an aqueous core that can encapsulate hydrophilic and hydrophobic drug molecules to be delivered to cells via endocytosis. This review will present new developments on instillations of liposomes and liposome-encapsulated drugs into the urinary bladder for treating lower urinary tract dysfunction.

Indexed as

Administration, IntravesicalAnimalsBotulinum Toxins, Type AHumansImmunosuppressive AgentsLiposomesNeurotoxinsTacrolimusUrinary Bladder DiseasesUrotheliumBotulinum Toxins, Type AImmunosuppressive AgentsLiposomesNeurotoxinsTacrolimusbladderbotulinum toxininterstitial cystitisliposomeoveractive bladder

Identifiers

PMID26999210
PMCPMC4810226
OpenAlexW2299276511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.